Arne Jahn

Dr. Arne Jahn

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PHPeter Horak
Peter Horak
CHChristoph Heining
Christoph Heining
SKSimon Kreutzfeldt
Simon Kreutzfeldt
BHBarbara Hutter
Barbara Hutter
AMAndreas Mock
Andreas Mock
SFStefan Fröhling
Stefan Fröhling
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population.Significance: Rare cancers are difficult to treat; in particular, molecular pathogenesis–oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials.See related commentary by Eggermont et al., p. 2677.This article is highlighted in the In This Issue feature, p. 2659

2 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLino Möhrmann
Lino Möhrmann
MWMaximilian Werner
Maximilian Werner
MOMałgorzata Oleś
Małgorzata Oleś
AMAndreas Mock
Andreas Mock
SUSebastian Uhrig
Sebastian Uhrig
HGHanno Glimm
Hanno Glimm
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis in 70 CUP patients to reveal substantial mutational heterogeneity with TP53, MUC16, KRAS, LRP1B and CSMD3 being the most frequently mutated known cancer-related genes. The most common fusion partner is FGFR2, the most common focal homozygous deletion affects CDKN2A. 56/70 (80%) patients receive genomics-based treatment recommendations which are applied in 20/56 (36%) cases. Transcriptome and methylome data provide evidence for the underlying entity in 62/70 (89%) cases. Germline analysis reveals five (likely) pathogenic mutations in five patients. Recommended off-label therapies translate into a mean PFS ratio of 3.6 with a median PFS1 of 2.9 months (17 patients) and a median PFS2 of 7.8 months (20 patients). Our data emphasize the clinical value of molecular analysis and underline the need for innovative, mechanism-based clinical trials.

12 May 2017 in EMBO Reports
Verified
Journal Article
Open access
PDF file
AJArne Jahn
Arne Jahn
GRGrishma Rane
Grishma Rane
MPMaciej Paszkowski‐Rogacz
Maciej Paszkowski‐Rogacz
SSSergi Sayols
Sergi Sayols
ABAlina Bluhm
Alina Bluhm
DKDennis Kappei
Dennis Kappei
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

11 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
LGLaura Gieldon
Laura Gieldon
DWDoreen William
Doreen William
KHKarl Hackmann
Karl Hackmann
WJWinnie Jahn
Winnie Jahn
AJArne Jahn
Arne Jahn
BKBarbara Klink
Barbara Klink
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with a strong hereditary background and a large genetic heterogeneity. Identification of the underlying genetic cause is crucial for the management of patients and their families as it aids differentiation between hereditary and sporadic cases. To improve diagnostics and clinical management we tailored an enrichment based comprehensive multi-gene next generation sequencing panel applicable to both analyses of tumor tissue and blood samples. We applied this panel to tumor samples and compared its performance to our current routine diagnostic approach. Routine diagnostic sequencing of 11 PPGL susceptibility genes was applied to blood samples of 65 unselected PPGL patients at a single center in Dresden, Germany. Predisposing germline mutations were identified in 19 (29.2%) patients. Analyses of 28 PPGL tumor tissues using the dedicated PPGL panel revealed pathogenic or likely pathogenic variants in known PPGL susceptibility genes in 21 (75%) cases, including mutations in IDH2, ATRX and HRAS. These mutations suggest sporadic tumor development. Our results imply a diagnostic benefit from extended molecular tumor testing of PPGLs and consequent improvement of patient management. The approach is promising for determination of prognostic biomarkers that support therapeutic decision-making.

11 April 2023 in Molecular Oncology
Verified
Journal Article
Open access
MTMaria-Veronica Teleanu
Maria-Veronica Teleanu
CFCarmina Teresa Fuss
Carmina Teresa Fuss
NPNagarajan Paramasivam
Nagarajan Paramasivam
SPSebastian Pirmann
Sebastian Pirmann
AMAndreas Mock
Andreas Mock
MKMatthias Kroiss
Matthias Kroiss
Parathyroid carcinoma (PC) is an ultra‐rare malignancy with a high risk of recurrence after surgery. Tumour‐directed systemic treatments for PC are not established. We used whole‐genome and RNA sequencing in four patients with advanced PC to identify molecular alterations that could guide clinical management. In two cases, the genomic and transcriptomic profiles provided targets for experimental therapies that resulted in biochemical response and prolonged disease stabilization: (a) immune checkpoint inhibition with pembrolizumab based on high tumour mutational burden and a single‐base substitution signature associated with APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide‐like) overactivation; (b) multi‐receptor tyrosine kinase inhibition with lenvatinib due to overexpression of FGFR1 (Fibroblast Growth Factor Receptor 1) and RET (Ret Proto‐Oncogene) and, (c) later in the course of the disease, PARP (Poly(ADP‐Ribose) Polymerase) inhibition with olaparib prompted by signs of defective homologous recombination DNA repair. In addition, our data provided new insights into the molecular landscape of PC with respect to the genome‐wide footprints of specific mutational processes and pathogenic germline alterations. These data underscore the potential of comprehensive molecular analyses to improve care for patients with ultra‐rare cancers based on insight into disease biology.

1 April 2020 in Pancreatology
Verified
Journal Article
Closed access
ABAnne Katrin Berger
Anne Katrin Berger
SMSadaf Shabbir Mughal
Sadaf Shabbir Mughal
MAMichael Allgäuer
Michael Allgäuer
CSChristoph Springfeld
Christoph Springfeld
THThilo Hackert
Thilo Hackert
CHChristoph Heining
Christoph Heining